Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ExelixisFRA:EX9 +3.50%90 OCF Margin % is 48.95% as of Jun. 2026, which is 42% above its 10-year median of 34.44. GuruFocus rates FRA:EX9 with a GF Score™ of 90/100 and a GF Value™ of €40.66 (Modestly Overvalued). The stock has 4 warning signs investors should review. Among 957 Biotechnology companies, Exelixis ranks better than 95.4% on this metric.
The historical data trend for Exelixis's OCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:EX9 vs MDGL, AXSM, ARWR: OCF Margin % Comparison
For the Biotechnology subindustry, Exelixis's OCF Margin %, along with its competitors' market caps and OCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Exelixis OCF Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Exelixis's OCF Margin % distribution charts can be found below:
* The bar in red indicates where Exelixis's OCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Exelixis (FRA:EX9) has a OCF Margin % of 48.95% as of Jun. 2026. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Exelixis and its competitors. This is 42% above median its historical median of 34.44. Over the past decade, Exelixis' OCF Margin % has ranged from 18.21 to 109.90. According to the industry distribution chart, Exelixis ranks #44 out of 957 companies in the Biotechnology industry, placing it in the top 4.6%.
Is Exelixis' OCF Margin % too high?
Exelixis' current OCF Margin % of 48.95% is 42% above median its 10-year median of 34.44. Over the past 10 years, this metric has ranged from a low of 18.21 to a high of 109.90. Based on the distribution chart, Exelixis ranks #44 out of 957 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Exelixis has a GF Score™ of 90/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Exelixis' OCF Margin % compare to MDGL and AXSM?
According to the Biotechnology industry distribution chart, Exelixis ranks #44 out of 957 companies for OCF Margin %. This places Exelixis in the top 5% of its industry — outperforming the majority of peers. Historically, Exelixis' own OCF Margin % has ranged from 18.21 to 109.90 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Margin % for a Biotechnology company?
A good OCF Margin % depends on the Biotechnology industry context. However, OCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Margin % mean?
A high OCF Margin % can signal that a stock is expensive relative to its fundamentals. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Exelixis and its competitors. Exelixis's current OCF Margin % is 48.95%, which is 42% above median its own 10-year median of 34.44. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Exelixis stock overvalued right now?
Based on GuruFocus' analysis, Exelixis (FRA:EX9) is currently considered Modestly Overvalued. The stock's GF Value™ is €40.66, compared to a current price of €46.16 — trading 13.5% above its estimated fair value. The current OCF Margin % is 48.95%, which is 42% above median its 10-year median of 34.44. Exelixis' overall GF Score™ is 90/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Margin % calculated?
OCF Margin % is calculated from a company's financial statements. For Exelixis (FRA:EX9), the current OCF Margin % is 48.95% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Exelixis (FRA:EX9) Overvalued in 2026?
Based on GuruFocus' analysis, Exelixis stock appears to be overvalued.
The current stock price of €46.16 is trading 13.5% above its estimated GF Value™ of €40.66.
GuruFocus considers Exelixis to be Modestly Overvalued.
Key valuation signals for FRA:EX9:
OCF Margin %: 48.95% (42% above median its 10-year median of 34.44)
GF Value™: €40.66 vs. price of €46.16 (13.5% above fair value)
No single metric tells the full story. See the FRA:EX9 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.
90GF Score
Get the complete analysis for FRA:EX9
OCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:EX9 has been successfully added to your 
